Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: Bio-Rad manufactures and supplies products and systems for life science research, healthcare, and analytical chemistry markets, focusing on separating, identifying, analyzing, and purifying complex chemical and biological materials.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $245.97 million | $210.18 million |
| Gross Profit | $142.71 million | $121.34 million |
| Gross Margin | 58.0% | 57.7% |
| Net Income | $26.36 million | $18.77 million |
| Diluted EPS | $1.01 | $0.73 |
| Operating Cash Flow | $21.72 million | $18.14 million |
| Cash and Equivalents (End of Period) | $25.22 million | $44.95 million |
| Total Debt (Current + Long-term) | $110.01 million | $N/A (Not explicitly aggregated in text) |
Note: Total debt calculated as Notes payable/current maturities ($11.15M) + Long-term debt ($98.86M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% year-over-year. Approximately $21.9 million of the $35.8 million increase was attributed to the weakening U.S. dollar.
- Segment Performance:
- Life Science: Sales rose 16.9% to $117.5 million; profit increased to $21.6 million.
- Clinical Diagnostics: Sales rose 16.9% to $126.1 million; profit increased to $18.8 million.
- Profitability: Net income increased 40% to $26.4 million. Gross margins improved slightly to 58.0%.
- Acquisitions: Acquired the chromatography column manufacturing business of Verdot Industrie for approximately $6 million in cash.
- Debt Reduction: Repurchased $6.7 million of Senior Subordinated Notes due in 2007, incurring $1.0 million in related costs.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes sales growth to organic expansion in process chromatography, food safety, and DNA amplification (Life Science) and quality controls and blood virus screening (Clinical Diagnostics). SG&A spending increased as a percentage of sales due to investments in personnel and marketing, though long-term goals remain to reduce this ratio.
- Liquidity: The company reported approximately $100 million available under its principal revolving credit agreement and $20.4 million under foreign lines of credit. Management believes cash flow and available credit are adequate for current objectives.
- Capital Expenditures: Net capital expenditures were $11.0 million, including $3.5 million capitalized for a new 166,000 sq. ft. facility in Hercules, California, scheduled for occupancy in early 2004.
- Risks: Forward-looking statements are subject to risks including the ability to develop new products, reliance on intellectual property, substantial leverage, competition, government regulation, and foreign monetary policies.
- Legal: The company is involved in various legal actions but does not believe any will have a material adverse effect on operations or financial position.
Investor Verification Checklist
- Currency Impact: Verify the extent to which the 17% sales growth is driven by the weakening U.S. dollar versus organic demand.
- Inventory Levels: Investigate the $6.5 million increase in net inventories, particularly the buildup in Clinical Diagnostics Quality Controls due to long lead times.
- Debt Servicing: Monitor the company's ability to service remaining debt obligations given the $110 million total debt load and the recent repurchase of notes.
- Capital Projects: Track the progress and cost overruns of the new Hercules, California facility ($25 million estimated cost).
- Stock-Based Compensation: Note that reported net income does not reflect stock-based compensation expense under SFAS 123; pro forma net income would be $25.8 million.